Although preclinical testing of stem cell therapies has shown promise, results achieved in animals are not necessarily indicative of what will occur in patients, and clinical studies in humans have been limited in size and number.
‘Stem cells secrete rejuvenating factors that can restore the health of stressed cells in the brain and can replace them.’
The potential value of stem cells and emerging therapeutic agents in neurodegenerative diseases are the focus of an article published in Rejuvenation Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Martina Nasello, Giuseppe Schirò, Floriana Crapanzano, and Carmela Rita Balistreri, University of Palermo, Italy, review the published literature and the most recent data evaluating the effectiveness of stem cells and other potential therapeutic compounds in the prevention and treatment of neurodegenerative pathologies.
The researchers discuss the potential advantages and obstacles for using different types of stem cells, including embryonic (ESC), mesenchymal (MSC), induced pluripotent (iPSC), and neuronal (NSC) stem cells as therapeutic agents. They also present the evidence to support further study of compounds such as metformin and melatonin hybrids, and of natural antioxidants including resveratrol, curcumin, and acetyl-L-carnitine.
"Especially at late stages, the main chronic neurodegenerative conditions of old age are characterized by the loss of neurons that the body does not replace; we need stem cell therapies to do that replacement," says Editor-in-Chief Aubrey D.N.J. de Grey, SENS Research Foundation, Mountain View, CA.
Stem cells also secrete rejuvenating factors that can restore the health of stressed cells at an earlier stage in such diseases.
Nasello et al. provide a terrific survey of where we stand and what remains to be developed in this critical area for the health of older people."